Jamiel Reyes

Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions

Alemtuzumab-based therapy was associated with high response rates in T-PLL—approximately 85% frontline—and approximately one-third of transplanted patients achieved long-term survival, which are descriptive benchmarks derived from low-certainty, single-arm evidence and require prospective confirmation.